8/26/2009

The FDA granted priority-review and orphan-drug designations for Salix Pharmaceuticals' rifaximin as a treatment for hepatic encephalopathy, a neurological complication of liver failure. Rifaximin, sold as the brand Xifaxan, already is approved to treat traveler's diarrhea.

Related Summaries